We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

169 hedge funds and large institutions have $655M invested in Ariad Pharmaceuticals Inc in 2014 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 44

4% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 24

0% more funds holding

Funds holding: 169169 (0)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

17% less capital invested

Capital invested by funds: $790M → $655M (-$135M)

23% less call options, than puts

Call options by funds: $20.5M | Put options by funds: $26.5M

Holders
169
Holders Change
Holders Change %
0%
% of All Funds
4.9%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.12%
New
25
Increased
61
Reduced
44
Closed
24
Calls
$20.5M
Puts
$26.5M
Net Calls
-$6.01M
Net Calls Change
-$11M
Name Holding Trade Value Shares
Change
Change in
Stake
AIG
76
American International Group
New York
$592K -$7.77K -1,330 -1%
DekaBank Deutsche Girozentrale
77
DekaBank Deutsche Girozentrale
Germany
$591K +$14.6K +2,500 +2%
Bank of America
78
Bank of America
North Carolina
$581K +$37.4K +6,411 +6%
6CM
79
683 Capital Management
New York
$540K
CM
80
Corvex Management
New York
$540K
HVC
81
Healthcare Value Capital
New Jersey
$540K +$146K +25,000 +33%
BA
82
BlackRock Advisors
Delaware
$534K -$236K -40,328 -29%
BG
83
BlackRock Group
United Kingdom
$525K +$129K +22,079 +29%
UBS AM
84
UBS AM
Illinois
$518K +$102K +17,500 +22%
VOYA Investment Management
85
VOYA Investment Management
Georgia
$491K
D.E. Shaw & Co
86
D.E. Shaw & Co
New York
$446K -$2.07M -353,653 -81%
LPL Financial
87
LPL Financial
California
$433K +$279K +47,719 +139%
Barclays
88
Barclays
United Kingdom
$422K -$17.7K -3,038 -3%
JG
89
Jefferies Group
New York
$405K -$1.07M -182,750 -71%
Public Employees Retirement Association of Colorado
90
Public Employees Retirement Association of Colorado
Colorado
$395K +$221K +37,904 +107%
DCC
91
Dow Chemical Company
Michigan
$378K -$526K -90,000 -56%
RB
92
Rodgers Brothers
Pennsylvania
$355K -$4.67K -800 -1%
VKH
93
Virtu KCG Holdings
New York
$347K -$149K -25,451 -28%
PA
94
Pinnacle Associates
New York
$335K -$4.5K -770 -1%
WMSA
95
Weiss Multi-Strategy Advisers
New York
$324K +$350K +60,000 New
AL
96
Airain Ltd
Guernsey
$309K +$334K +57,246 New
QSS
97
Quantitative Systematic Strategies
Florida
$293K +$304K +52,083 New
PCM
98
Piermont Capital Management
Missouri
$291K +$315K +53,980 New
Nomura Asset Management
99
Nomura Asset Management
Japan
$270K
T. Rowe Price Associates
100
T. Rowe Price Associates
Maryland
$257K

ARIA Hedge Fund Activity: Q3 2014 in Review

169 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q3 2014, worth a combined $655M — down 17% from $790M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ARIA positions and 24 closed out — a net gain of 1 holder — while 61 added to existing stakes and 44 trimmed.

The largest buyer was Columbus Circle Investors, opening a new position worth an estimated $13.6M. The largest seller was Franklin Resources, exiting entirely with an estimated $32.1M sold.

  • 169 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q3 2014, unchanged from Q2 2014.
  • Funds reported $655M of Ariad Pharmaceuticals Inc stock for Q3 2014, down 17% quarter-over-quarter.
  • 25 funds opened new Ariad Pharmaceuticals Inc positions in Q3 2014 and 24 closed out, a net change of +1 holder.
  • The largest Ariad Pharmaceuticals Inc buyer in Q3 2014 was Columbus Circle Investors, an estimated $13.6M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q3 2014 was Franklin Resources, an estimated $32.1M sold.

Based on aggregated 13F filings for Q3 2014.